The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

OXDRALAZINE     2-[(6-hydrazinylpyridazin-3- yl)-(2...

Synonyms: di-HCl, AG-K-85639, AC1Q3APA, CTK4F9729, AR-1D0910, ...
This record was replaced with 28434.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of L 6150


High impact information on L 6150

  • The triple regimen reduced blood pressure 35/15 mm Hg after one month (daily doses 25 mg chlorthalidone, 20 mg oxdralazine, 40 mg propranolol), and further increase in dosages caused a reduction of 45/24 mm Hg at the third month (daily doses 25 mg chlorthalidone, 56 +/- 20 mg oxdralazine, 112 +/- 40 mg propranolol) [2].
  • This combination seems particularly successful since propranolol will prevent the undesired rise in cardiac output due to oxdralazine as well as the activation of the renin-angiotensin axis due to diuretics [3].
  • Blood pressure did not return to normal limits in 15 patients, who were continued on the same protocol plus 10 to 50 mg oxdralazine q.d. After an average of 68 +/- 35 days blood pressure fell from 180/110 mm Hg to 145/90 mm Hg without orthostatism, significant side effects, or changes in GFR [3].
  • Effect of 3-hydrazino-6[N, N-bis (2-hydroxyethyl) amino]-pyridazine (L 6150) on renin in hypertensive rats [4].

Chemical compound and disease context of L 6150


Associations of L 6150 with other chemical compounds


  1. Hemodynamic effects of oxdralazine and hydralazine in hypertension. Moskowitz, R.M., Cohn, J.N. Clin. Pharmacol. Ther. (1980) [Pubmed]
  2. A crossover trial of oxdralazine in hypertension. Salvadeo, A., Villa, G., Segagni, S., Galli, F., Criscuolo, D. Journal of clinical pharmacology. (1983) [Pubmed]
  3. Oxdralazine, a new peripheral vasodilator, combined with propranolol and hydrochlorothiazide: a rational approach to antihypertensive treatment. Bartoli, E., Faedda, R., Arras, S., Satta, A., Soggia, G. Journal of clinical pharmacology. (1979) [Pubmed]
  4. Effect of 3-hydrazino-6[N, N-bis (2-hydroxyethyl) amino]-pyridazine (L 6150) on renin in hypertensive rats. Kawashima, K., Watanabe, T.X., Sokabe, H. Jpn. J. Pharmacol. (1980) [Pubmed]
  5. Comparative study of oxdralazine and dihydralazine in essential hypertension. Salvadeo, A., Villa, G., Segagni, S., Piazza, W., Criscuolo, D. International journal of clinical pharmacology, therapy, and toxicology. (1981) [Pubmed]
WikiGenes - Universities